265 related articles for article (PubMed ID: 27431093)
1. Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy.
Sociali G; Visigalli D; Prukop T; Cervellini I; Mannino E; Venturi C; Bruzzone S; Sereda MW; Schenone A
Neurobiol Dis; 2016 Nov; 95():145-57. PubMed ID: 27431093
[TBL] [Abstract][Full Text] [Related]
2. P2X7-mediated increased intracellular calcium causes functional derangement in Schwann cells from rats with CMT1A neuropathy.
Nobbio L; Sturla L; Fiorese F; Usai C; Basile G; Moreschi I; Benvenuto F; Zocchi E; De Flora A; Schenone A; Bruzzone S
J Biol Chem; 2009 Aug; 284(34):23146-58. PubMed ID: 19546221
[TBL] [Abstract][Full Text] [Related]
3. The diadenosine homodinucleotide P18 improves in vitro myelination in experimental Charcot-Marie-Tooth type 1A.
Nobbio L; Visigalli D; Mannino E; Fiorese F; Kassack MU; Sturla L; Prada V; De Flora A; Zocchi E; Bruzzone S; Schenone A
J Cell Biochem; 2014 Jan; 115(1):161-7. PubMed ID: 23959806
[TBL] [Abstract][Full Text] [Related]
4. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
Chumakov I; Milet A; Cholet N; Primas G; Boucard A; Pereira Y; Graudens E; Mandel J; Laffaire J; Foucquier J; Glibert F; Bertrand V; Nave KA; Sereda MW; Vial E; Guedj M; Hajj R; Nabirotchkin S; Cohen D
Orphanet J Rare Dis; 2014 Dec; 9():201. PubMed ID: 25491744
[TBL] [Abstract][Full Text] [Related]
5. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy.
Meyer zu Horste G; Prukop T; Liebetanz D; Mobius W; Nave KA; Sereda MW
Ann Neurol; 2007 Jan; 61(1):61-72. PubMed ID: 17262851
[TBL] [Abstract][Full Text] [Related]
6. Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).
Prukop T; Stenzel J; Wernick S; Kungl T; Mroczek M; Adam J; Ewers D; Nabirotchkin S; Nave KA; Hajj R; Cohen D; Sereda MW
PLoS One; 2019; 14(1):e0209752. PubMed ID: 30650121
[TBL] [Abstract][Full Text] [Related]
7. Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot-Marie-Tooth disease type 1A (CMT1A) rats.
Prukop T; Wernick S; Boussicault L; Ewers D; Jäger K; Adam J; Winter L; Quintes S; Linhoff L; Barrantes-Freer A; Bartl M; Czesnik D; Zschüntzsch J; Schmidt J; Primas G; Laffaire J; Rinaudo P; Brureau A; Nabirotchkin S; Schwab MH; Nave KA; Hajj R; Cohen D; Sereda MW
J Neurosci Res; 2020 Oct; 98(10):1933-1952. PubMed ID: 32588471
[TBL] [Abstract][Full Text] [Related]
8. Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs.
Hanemann CO; Gabreëls-Festen AA; Stoll G; Müller HW
Acta Neuropathol; 1997 Oct; 94(4):310-5. PubMed ID: 9341930
[TBL] [Abstract][Full Text] [Related]
9. Farnesol Ameliorates Demyelinating Phenotype in a Cellular and Animal Model of Charcot-Marie-Tooth Disease Type 1A.
Park NY; Kwak G; Doo HM; Kim HJ; Jang SY; Lee YI; Choi BO; Hong YB
Curr Issues Mol Biol; 2021 Nov; 43(3):2011-2021. PubMed ID: 34889893
[TBL] [Abstract][Full Text] [Related]
10. Proliferation of Schwann cells and regulation of cyclin D1 expression in an animal model of Charcot-Marie-Tooth disease type 1A.
Atanasoski S; Scherer SS; Nave KA; Suter U
J Neurosci Res; 2002 Feb; 67(4):443-9. PubMed ID: 11835311
[TBL] [Abstract][Full Text] [Related]
11. Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease.
Nobbio L; Vigo T; Abbruzzese M; Levi G; Brancolini C; Mantero S; Grandis M; Benedetti L; Mancardi G; Schenone A
Neurobiol Dis; 2004 Jun; 16(1):263-73. PubMed ID: 15207283
[TBL] [Abstract][Full Text] [Related]
12. Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies.
Hanemann CO; Stoll G; D'Urso D; Fricke W; Martin JJ; Van Broeckhoven C; Mancardi GL; Bartke I; Müller HW
J Neurosci Res; 1994 Apr; 37(5):654-9. PubMed ID: 8028042
[TBL] [Abstract][Full Text] [Related]
13. Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease.
Grandis M; Leandri M; Vigo T; Cilli M; Sereda MW; Gherardi G; Benedetti L; Mancardi G; Abbruzzese M; Nave KA; Nobbio L; Schenone A
Exp Neurol; 2004 Nov; 190(1):213-23. PubMed ID: 15473994
[TBL] [Abstract][Full Text] [Related]
14. Axonal damage and demyelination in long-term dorsal root ganglia cultures from a rat model of Charcot-Marie-Tooth type 1A disease.
Nobbio L; Gherardi G; Vigo T; Passalacqua M; Melloni E; Abbruzzese M; Mancardi G; Nave KA; Schenone A
Eur J Neurosci; 2006 Mar; 23(6):1445-52. PubMed ID: 16553608
[TBL] [Abstract][Full Text] [Related]
15. Impaired expression of ciliary neurotrophic factor in Charcot-Marie-Tooth type 1A neuropathy.
Nobbio L; Fiorese F; Vigo T; Cilli M; Gherardi G; Grandis M; Melcangi RC; Mancardi G; Abbruzzese M; Schenone A
J Neuropathol Exp Neurol; 2009 May; 68(5):441-55. PubMed ID: 19525893
[TBL] [Abstract][Full Text] [Related]
16. Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice.
Klein D; Patzkó Á; Schreiber D; van Hauwermeiren A; Baier M; Groh J; West BL; Martini R
Brain; 2015 Nov; 138(Pt 11):3193-205. PubMed ID: 26297559
[TBL] [Abstract][Full Text] [Related]
17. Soluble Neuregulin1 is strongly up-regulated in the rat model of Charcot-Marie-Tooth 1A disease.
Fornasari BE; Ronchi G; Pascal D; Visigalli D; Capodivento G; Nobbio L; Perroteau I; Schenone A; Geuna S; Gambarotta G
Exp Biol Med (Maywood); 2018 Feb; 243(4):370-374. PubMed ID: 29350067
[TBL] [Abstract][Full Text] [Related]
18. Animal models of Charcot-Marie-Tooth disease type 1A.
Sereda MW; Nave KA
Neuromolecular Med; 2006; 8(1-2):205-16. PubMed ID: 16775377
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of Charcot-Marie-Tooth 1A (CMT1A) neuropathy.
Hanemann CO; Müller HW
Trends Neurosci; 1998 Jul; 21(7):282-6. PubMed ID: 9683317
[TBL] [Abstract][Full Text] [Related]
20. Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A.
Perea J; Robertson A; Tolmachova T; Muddle J; King RH; Ponsford S; Thomas PK; Huxley C
Hum Mol Genet; 2001 May; 10(10):1007-18. PubMed ID: 11331611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
